@suelannon , sorry for the slow reply; I've been out of town a couple days.

Dealing w/ pancan since initial stage-II diagnosis 3 1/2 years ago. Six months of Folfirinox, then had the Whipple 3 years ago, reported all clear post-op, but had a recurrence that went metastatic 4 months after that. I've been on Gem/Abrax/Cisplatin the last 2.5 years with good control, except for the 4-month clinical trial break during which the disease advanced rapidly.

I only took "a tiny dose" of Ivermectin (12 mg) on chemo day in January and February, which was once every two weeks, and experienced no side effects, but my CA19-9 remained stable under 100 during that little two-month experiment. My CA19-9 has risen to about 500 in the two months since I stopped, and MRI this week found evidence of disease progression. Despite some correlation, I can NOT claim this is clear cause and effect -- it was not a well-controlled experiment, and I can identify several factors that may have had a role in my status changing.

Regarding dosing, the above amount (12 mg) comes to 0.16 mg / kg given my body mass of approximately 72 kg. And to repeat, that's only once every two weeks.

Some of the biggest Ivermectin proponents on the web are pushing doses of 1-2 mg/kg (which would be 72 mg - 144 mg every day; yes, that's 6-12 times the dose I took, and 14 times more often, so it's a significant increase with all sorts of potential side effects.

Some of the biggest Ivermectin proponents on the web also appear on https://quackwatch.org/ , so beware!

Since I have ZERO MEDICAL TRAINING, I won't recommend this to anyone, FULL STOP!

I've run into obstacles getting my own prescription refilled, so I have ZERO experience with it other than the small dose and short-term use cited above.

But I'm also running into obstacles with clinical trial applications, and being stage-IV with disease progression and chemo resistance, I remain open-minded about taking the risk FOR MYSELF, and I commit to posting the good, the bad, and the ugly if I get that far.

Stay tuned! 🙂